Exact Sciences Goes Full Wu-Tang On Wall Street

Published by
The Street

By Maxx Chatsko Cash rules everything around the diagnostics leader, which pledged to prioritize profitable growth. Cancer diagnostics powerhouse Exact Sciences (EXAS) – Get Exact Sciences Corporation Report appears on track to easily beat full-year 2022 revenue guidance. Despite the trend through the first half of the year, management opted to maintain guidance set in May. That prompted a few questions from analysts on the conference call to discuss second-quarter 2022 operating results. “Why the conservatism?,” asked one analyst. Management had a simple reply: “Cash rules everything around m…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street